Zhang, J., Jex, E., Feng, T., Sivko, G. S., Baillie, Les ORCID: https://orcid.org/0000-0002-8186-223X, Goldman, S., Van Kampen, K. R. and Tang, D.-C. C. 2013. An adenovirus-vectored nasal vaccine confers rapid and sustained protection against Anthrax in a single-dose regimen. Clinical and Vaccine Immunology 20 (1) , pp. 1-8. 10.1128/CVI.00280-12 |
Preview |
PDF
- Published Version
Download (1MB) | Preview |
Abstract
Bacillus anthracis is the causative agent of anthrax, and its spores have been developed into lethal bioweapons. To mitigate an onslaught from airborne anthrax spores that are maliciously disseminated, it is of paramount importance to develop a rapid-response anthrax vaccine that can be mass administered by nonmedical personnel during a crisis. We report here that intranasal instillation of a nonreplicating adenovirus vector encoding B. anthracis protective antigen could confer rapid and sustained protection against inhalation anthrax in mice in a single-dose regimen in the presence of preexisting adenovirus immunity. The potency of the vaccine was greatly enhanced when codons of the antigen gene were optimized to match the tRNA pool found in human cells. In addition, an adenovirus vector encoding lethal factor can confer partial protection against inhalation anthrax and might be coadministered with a protective antigen-based vaccine.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Pharmacy |
Subjects: | R Medicine > RS Pharmacy and materia medica |
Additional Information: | Pdf uploaded in accordance with publisher's policy at http://www.sherpa.ac.uk/romeo/issn/1556-6811/ (accessed 24/02/2014) |
Publisher: | American Society for Microbiology |
ISSN: | 1556-6811 |
Date of First Compliant Deposit: | 30 March 2016 |
Last Modified: | 05 May 2023 07:49 |
URI: | https://orca.cardiff.ac.uk/id/eprint/46956 |
Citation Data
Cited 22 times in Scopus. View in Scopus. Powered By Scopus® Data
Actions (repository staff only)
Edit Item |